These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19647079)

  • 1. P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration.
    Emul M; Dalkiran M; Coskun O; Yavuz R; Tosun M; Duran A; Ugur M; Keles I
    Pharmacol Res; 2009 Nov; 60(5):369-72. PubMed ID: 19647079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
    Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
    CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A
    J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone: first year experience in a hospital setting.
    Centorrino F; MacLean E; Salvatore P; Kidwell JE; Fogarty KV; Berry JM; Baldessarini RJ
    J Psychiatr Pract; 2004 Nov; 10(6):361-7. PubMed ID: 15583517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk of QTc prolongation due to combination of ziprasidone and quetiapine].
    Minov C
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S142-4. PubMed ID: 15570533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose ziprasidone associated with QT interval prolongation.
    Witsil JC; Zell-Kanter M; Mycyk MB
    Am J Emerg Med; 2012 Jun; 30(5):837.e1-2. PubMed ID: 21641143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
    Taylor D
    CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT interval duration and dispersion in children and adolescents treated with ziprasidone.
    Correll CU; Lops JD; Figen V; Malhotra AK; Kane JM; Manu P
    J Clin Psychiatry; 2011 Jun; 72(6):854-60. PubMed ID: 21457682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
    Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
    Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.
    Eker SS; Sarandol A; Akkaya C; Sivrioglu EY; Kirli S
    J Psychopharmacol; 2009 Nov; 23(8):993-6. PubMed ID: 18635710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
    Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.
    Kelly DL; Love RC
    Psychopharmacol Bull; 2001; 35(4):66-79. PubMed ID: 12397857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-Four-Hour Measures of Heart Rate-Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment.
    Tümüklü MN; Tümüklü MM; Nesterenko V; Jayathilake K; Beasley CM; Meltzer HY
    J Clin Psychopharmacol; 2019; 39(2):100-107. PubMed ID: 30707117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL; Su TP; Chou YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial.
    Mautone A; Scarone S;
    Pharmacopsychiatry; 2011 Jul; 44(5):173-8. PubMed ID: 21751127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.